Shares of Mesoblast Ltd (MESO) jumped more than 8% in after-hours trading on Thursday after the company reported continued strong quarterly growth in sales of its flagship product, Ryoncil.
Ryoncil, indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older, is the first FDA-approved mesenchymal stromal cell (MSC) therapy. It was approved by the FDA in December 2024.
For the quarter ended December 31, 2025, Ryoncil generated gross revenue of US$35.1 million, representing a 60% increase from the prior quarter.
The increase in quarterly revenues is likely to bolster Mesoblast's recent announcement of entering into a $125 million facility with its largest shareholder, which markedly lowered the company's cost of capital and freed up its major assets to provide flexibility for strategic partnerships and commercialisation.
Also, the new facility enabled Mesoblast to repay in full its prior senior secured loan. Moreover, Mesoblast partly repaid the subordinated royalty facility, which will continue to reduce from ongoing revenue and will be fully repaid by mid-CY2026.
"Our strong balance sheet, continued growth in quarterly sales of Ryoncil, and a new lower-cost financing facility provide greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil," said Mesoblast Chief Executive Dr. Silviu Itescu.
MESO closed Thursday's trade at $19.87, up 3.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.